Plant originated solutions for every day ailments

Romeg Therapeutics is dedicated to addressing high unmet medical needs through the development of innovative therapies. The company focuses on providing novel drug products that enhance treatment options for patients and healthcare providers. One of their key offerings is Gloperba®, an FDA-approved oral solution designed for the prophylactic treatment of gout flares in adults. This product, which contains 0.6mg of colchicine per 5mL, is notable for its liquid dosage form, which allows for greater dosing flexibility, catering to the specific needs of patients suffering from gout.

The prevalence of gout is a significant concern, affecting approximately 8.3 million individuals in the United States alone, with many remaining undiagnosed due to a lack of awareness about the condition. As the aging population continues to grow, the number of gout patients is expected to rise, highlighting the importance of effective treatment options. Romeg Therapeutics, through its partnership with Scilex Pharmaceuticals, aims to transform the management of gout by providing accessible and effective therapeutic solutions, thereby improving patient outcomes in this underserved area of healthcare.

United States

Romeg Therapeutics is an innovative biopharmaceutical company with a focus on targeting high unmet need indications historically overlooked by the pharmaceutical industry.

Romeg Therapeutics

Company Details